Table 3 Frequency of laboratory monitoring of methotrexate in each stage of respondents’ preferred schedule by respondent percentage, N = 188#
Schedule (N, %)* | Weekly (N, %)* | Every 2 Weeks (N, %)* | Monthly (N, %)* | Every 2 Months (N, %)* | Every 3 Months (N, %)* | Every 4 Months (N, %)* | Every 6 Months (N, %)* | Yearly (N, %)* |
|---|---|---|---|---|---|---|---|---|
1 Stage (27, 14%) | ||||||||
Stage 1 | 0 (0%) | 0 (0%) | 7 (26%) | 4 (15%) | 13 (48%) | 3 (11%) | 0 (0%) | 0 (0%) |
2 Stages (82, 44%) | ||||||||
Stage 1 | 1 (1%) | 10 (12%) | 63 (77%) | 4 (5%) | 4 (5%) | 0 (0%) | 0 (0%) | 0 (0%) |
Stage 2 | 0 (0%) | 0 (0%) | 7 (9%) | 9 (11%) | 61 (74%) | 2 (2%) | 1 (1%) | 2 (2%) |
3 Stages (63, 34%) | ||||||||
Stage 1 | 4 (6%) | 35 (56%) | 23 (37%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 0 (0%) |
Stage 2 | 0 (0%) | 1 (2%) | 33 (52%) | 20 (32%) | 8 (13%) | 0 (0%) | 1 (2%) | 0 (0%) |
Stage 3 | 0 (0%) | 0 (0%) | 0 (0%) | 4 (6%) | 51 (81%) | 3 (5%) | 3 (5%) | 2 (3%) |
4 Stages (16, 9%) | ||||||||
Stage 1 | 0 (0%) | 4 (25%) | 11 (69%) | 0 (0%) | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Stage 2 | 0 (0%) | 0 (0%) | 6 (38%) | 5 (31%) | 4 (25%) | 0 (0%) | 1 (6%) | 0 (0%) |
Stage 3 | 0 (0%) | 0 (0%) | 3 (19%) | 4 (25%) | 6 (38%) | 1 (6%) | 2 (13%) | 0 (0%) |
Stage 4 | 0 (0%) | 0 (0%) | 2 (13%) | 0 (0%) | 10 (63%) | 1 (6%) | 2 (13%) | 1 (6%) |